Dr. Osborne is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3410 worth street
400
Dallas, TX 75246Phone+1 214-370-1052Fax+1 972-370-1850- Is this information wrong?
Education & Training
University of Texas Medical Branch HospitalsFellowship, Geriatric Medicine (Internal Medicine), 2001 - 2002- University of Texas Medical Branch HospitalsFellowship, Medical Oncology, 1999 - 2001
- University of Texas Medical Branch HospitalsResidency, Internal Medicine, 1996 - 1999
University of Texas Medical Branch School of MedicineClass of 1996
Certifications & Licensure
TX State Medical License 1999 - 2024- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Ixabepilone + Carboplatin Metastatic Breast Cancer Start of enrollment: 2010 Jan 01
- A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
- A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Publications & Presentations
PubMed
- 18 citationsTrastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis.Guy Jerusalem, Yeon Hee Park, Toshinari Yamashita, Sara A Hurvitz, Shanu Modi, Fabrice Andre, Ian E Krop, Xavier Gonzàlez Farré, Benoit You, Cristina Saura, Sung-Bae K...> ;Cancer Discovery. 2022 Dec 2
- 52 citationsPhase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.Aditya Bardia, Virginia G. Kaklamani, Sharon Wilks, Amy Weise, Donald A. Richards, Wael A. Harb, Cynthia Osborne, Robert Wesolowski, Meghan Sri Karuturi, Paul Conkling...> ;Journal of Clinical Oncology. 2021 Jan 29
- 60 citationsPhase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancerJennifer R. Diamond, Donald A. Richards, Alain C. Mita, Cynthia Osborne, Joyce O'Shaughnessy, Chun Zhang, Randall Henner, Ann M. Kapoun, Lu Xu, Bob Stagg, Shailaja Utt...> ;Breast Cancer Research and Treatment. 2020 Aug 14
- Join now to see all
Press Mentions
Day Care Will Never Be Germ-Free. But We Can Make It Less GrossDecember 16th, 2022- Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01February 15th, 2024
- Orally Bioavailable SERD Shows Promise in Certain Breast Cancer PatientsJanuary 31st, 2021
Hospital Affiliations
Baylor University Medical CenterDallas, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
